z-logo
Premium
Cutaneous focal mucinosis – a histopathological an immunohistochemical analysis of 11 cases
Author(s) -
Wilk Michael,
Schmoeckel Christian
Publication year - 1994
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.1600-0560.1994.tb00287.x
Subject(s) - pathology , vimentin , lesion , immunohistochemistry , fibroblast , s100 protein , histogenesis , cd34 , desmin , mucin , biology , mucinosis , histology , medicine , cell culture , stem cell , microbiology and biotechnology , genetics
The histogenesis of cutaneous local mucinosis (CFM) is controversial. Eleven cases of CFM (5F, 6M; mean age 51 years) from our routine files between 1986 and the present time have, therefore, been examined histopathologically and immunohistochemically. Histology revealed an increased number of fibroblast‐like cells in early lesions, whereas they were diminished or predominantly at the margin in advanced ones. The myxomatous areas showed slight to absent reticulum formation. Similarly, elastic fibers were almost absent, and collagen fibers were fragmented and replaced by variable amounts of mucin. One specimen revealed an epithelial component within the lesion reminiscent of a poorly induced trichofolliculoma. Immunohistochemically, vimentin was consistently present and correlated with the number of fibroblast‐like cells. A few (<5%) CD34 + dermal dendritic cells (DDs) were locally seen within CFM. In contrast, FXIIIa + DDs accounted for up to 30%. Fibroblasl‐like cells were negative for S‐100 protein, Leu7, desmin and α‐SMA. The epithelial component within one of our specimens seems to have been induced by CFM and is a feature also seen in (angio)‐myxomas. CFM appears to be a mesenchymally derived lesion composed predominantly of fibroblasts. DDs do not form the major cell component but rather seem passively incorporated.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here